Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

5(71.4%)

Phase 1

2(28.6%)

7Total

Early Phase 1(5)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06708936Early Phase 1Withdrawn

KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study

Role: lead

NCT07532746Phase 1Not Yet Recruiting

A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies

Role: lead

NCT05635591Phase 1Enrolling By Invitation

KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial

Role: collaborator

NCT06752473Early Phase 1Not Yet Recruiting

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Role: lead

NCT05882305Early Phase 1Withdrawn

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial

Role: lead

NCT06370026Early Phase 1Not Yet Recruiting

KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial

Role: collaborator

NCT06097793Early Phase 1Recruiting

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Role: lead

All 7 trials loaded